KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $8.5 billion.

  • Teva Pharmaceutical Industries' Cost of Revenue fell 0.32% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 billion, marking a year-over-year decrease of 0.46%. This contributed to the annual value of $8.5 billion for FY2024, which is 3.43% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Cost of Revenue stood at $8.5 billion for FY2024, which was up 3.43% from $8.2 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' Cost of Revenue's 5-year high stood at $8.9 billion during FY2020, with a 5-year trough of $8.0 billion in FY2022.
  • Its 3-year average for Cost of Revenue is $8.2 billion, with a median of $8.2 billion in 2023.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Cost of Revenue fell by 7.27% in 2021, and later grew by 3.43% in 2024.
  • Teva Pharmaceutical Industries' Cost of Revenue (Yearly) stood at $8.9 billion in 2020, then dropped by 7.27% to $8.3 billion in 2021, then dropped by 4.01% to $8.0 billion in 2022, then climbed by 3.12% to $8.2 billion in 2023, then grew by 3.43% to $8.5 billion in 2024.